Antibiotic/COPD in Acute Exacerbation of Chronic Obstructive Pulmonary Disease (COPD) Requiring Mechanical Ventilation

Chronic Obstructive Pulmonary Disease Clinical Trial

Official title:

Antibiotic Comparison Exacerbation COPD

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00791505
• Other study ID #: 04/UR/08-20
• Status: Completed
• Phase: Phase 3
• Start date: July 2002
• Est. completion date: June 2005

Study information

• Verified date: February 2020
• Source: University of Monastir
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Although the use of antibiotics in the treatment of acute exacerbation of chronic obstructive pulmonary disease (COPD) is largely accepted, controversy remains regarding whether the choice of antibiotic has any impact on outcome. Our aim was to compare the effects of the combination of trimethoprim and sulfamethoxazole and ciprofloxacin in patients treated for severe COPD exacerbation requiring mechanical ventilation.

Description:

Antibiotic therapy has been shown to be beneficial in patients with severe acute exacerbation of chronic obstructive pulmonary disease (COPD). Although recent guidelines support the use of new antibiotics there is no evidence that newer antibiotics are any better than older agents. The choice of antibiotic to be used in this situation is challenging to the clinician who must choose between traditional antibiotics (cyclins, aminopénicillins, cotrimoxazole...) and new antimicrobial agents. Indeed, available comparative studies did not show an obvious superiority of new antibiotics compared to their predecessors . Taking into account bacterial agents associated to COPD exacerbations, one must choose an antibiotic which has the best activity against Haemophilus influenzae, Streptococcus pneumoniae and Branhamella catarrhalis. News quinolones are represented as an interesting alternative to standard antibiotics because of their large spectrum of action and of their pharmacokinetic advantages allowing high tissue penetration in the pulmonary parenchyma and tracheobronchial tree. Data on their use among patients having moderate exacerbation of COPD are encouraging but their effectiveness in more severe presentations is not established. The objective of this randomized controlled and double blind study is to evaluate the effectiveness and tolerance of ciprofloxacin compared to trimethoprim sulfamethoxazole in patients admitted to ICU for severe exacerbation of COPD requiring mechanical ventilation.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 170
• Est. completion date: June 2005
• Est. primary completion date: June 2005
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• All patients having a COPD (according to the definition of the American Thoracic Society) and having an acute exacerbation leading to an acute respiratory failure requiring the admission to ICU and mechanical ventilation.

• The acute exacerbation of COPD is defined by increase in the frequency of cough, the volume and the purulence of expectoration and increase of baseline dyspnea. To be included, patients must have respiratory rate >30 cycles/min and one of the following blood gas criteria (with blood gases performed right before the initiation of mechanical ventilation): PaC02 > 6kPa and arterial pH <7.30.

Exclusion Criteria:

• Pneumonia documented with chest radiography

• Antibiotic treatment in the ten previous days of ICU admission

• Former inclusion in the study

• History of allergy to the quinolones and/or to trimethoprim sulfamethoxazole

• Pregnancy or breast feeding

• Severe chronic disease: heart, liver, kidney.

• Known immunodeficiency (malignant hemopathy, AIDS...)

• Digestive disease which could affect the absorption of the drugs

• Concomitant infection which requires systemic antibiotic treatment

Related Conditions & MeSH terms

• Antibiotics
• Chronic Obstructive Pulmonary Disease
• Lung Diseases
• Lung Diseases, Obstructive
• Pulmonary Disease, Chronic Obstructive
• Sepsis

Intervention

Drug:
• ciprofloxacin
1500 mg a day for 10 days
• trimethoprim-sulfamethoxazole
2000 mg a day for 10 days

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
University of Monastir

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Two major criteria will be used for the determination of sample size and the estimate of the effectiveness of the treatments of the study: 1. mortality (in ICU and in the hospital) 2. rate of additional antibiotherapy course.	The decision to initiate new antibiotics was left to the discretion of the treating physician, and if resistant species were cultured, the protocol treatment was not systematically changed unless the clinical course of the patient worsened	30 day after starting protocol
Secondary	Mechanical ventilation duration	duration of mechanical ventilation	30 days after starting protocol
Secondary	Duration of hospital stay	duration of hospital stay	30 days after starting protocol